Creative Biolabs stands as a premier service provider with a comprehensive sdAb development platform. Our seasoned scientists are committed to advancing TCR-like sdAb development, significantly enhancing the success of your projects.
Using our advanced technologies, we will meet the specific requirements of each pathway and offer accurate results to our customers.
TCR-Like SdAb
T-cell receptors detect target antigens which appear as peptides on MHC I or MHC II molecules, including tumor-specific antigens derived from intracellular proteins that proteasomes break down. TCR-like single-domain antibodies (sdAbs) have become available to resolve soluble TCR expression and low target affinity problems because they deliver superior antigen-binding specificity and productivity.
The unique combination of high affinity and specificity for pMHC complexes, along with their ability to recognize covert epitopes and having low immunogenicity, good solubility, and high stability, makes these sdAbs effective for both diagnostic and therapeutic use. The combination of high yields and straightforward production amplifies their potential, while their incorporation into CAR-T cells improves recognition specificity for MHC/peptide complexes and modifies the immune-suppressive environment. The therapeutic capabilities and functional adaptability of sdAbs expand to include intracellular protein recognition through TCR-like sdAbs, which broadens therapeutic options for diseases such as cancer, and companies like Creative Biolabs deliver development expertise for drug production needs.
Typical Pathway for TCR-Like SdAb Development
Phase I Discovery
Target IdentificationMultiple target identification processes can be provided upon your request.
Typical Features of One-Stop for TCR-Like sdAb Development
Advanced technical platform in dealing with challenging targets
Comprehensive strategies to formulate the most suitable solutions for TCR-like sdAb
Experienced professional team with a wealth of knowledge
Fully customizable design to meet specific demands
Fast turnaround time
Reliable lab report with timely update
Affordable price with the best quality
Creative Biolabs is a leading servicer with many years of experience in the field of sdAb development. Leveraging our advanced sdAb development platforms, Creative Biolabs offers bespoke solutions for TCR-like sdAb, effectively supporting
your sdAb therapeutics development. To promote your TCR-related projects, please contact us for further information.
Reference
Yang, Xiaofeng, et al. "Opportunities and challenges for antibodies against intracellular antigens." Theranostics 9.25 (2019): 7792. Distributed under Open Access license CC BY 4.0 , without modification.
Case Study
In this case study, Biotinylated target MHC-mutant peptide was used as screening target. By using our premade CaVHHL-S2™ library, the target-specific sdAb binders were isolated.
Figure 1. Process monitoring of library screening stage.
In this case study, in-solution screening strategy was used. Positive selection for biotinylated target MHC-peptide, control MHC-peptide was used as competitor to further remove the binders that bound to the control MHC-peptide. After five rounds of biopanning, good enrichment was observed for the target, and a clear difference was found between the "Target Coating" group and the "No Coating" control.
Figure 2. Summary of monoclonal phage ELISA of the randomly picked clones and DNA sequencing.
After the whole biopanning, 92 clones were randomly picked for monoclonal phage ELISA, and 28 positive clones were observed for DNA sequencing. Finally, 4 unique clones were obtained.
Figure 1. Process monitoring of library screening stage.
Figure 2. Summary of monoclonal phage ELISA of the randomly picked clones and DNA sequencing.
